RT Journal Article
SR Electronic
T1 Kynurenic acid underlies sex-specific immune responses to COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.06.20189159
DO 10.1101/2020.09.06.20189159
A1 Yuping Cai
A1 Daniel J. Kim
A1 Takehiro Takahashi
A1 David I. Broadhurst
A1 Shuangge Ma
A1 Nicholas J.W. Rattray
A1 Arnau Casanovas-Massana
A1 Benjamin Israelow
A1 Jon Klein
A1 Carolina Lucas
A1 Tianyang Mao
A1 Adam J. Moore
A1 M. Catherine Muenker
A1 Jieun Oh
A1 Julio Silva
A1 Patrick Wong
A1 Yale IMPACT Research team
A1 Albert I. Ko
A1 Sajid A. Khan
A1 Akiko Iwasaki
A1 Caroline H. Johnson
YR 2020
UL http://medrxiv.org/content/early/2020/09/08/2020.09.06.20189159.abstract
AB Coronavirus disease-2019 (COVID-19) has poorer clinical outcomes in males compared to females, and immune responses underlie these sex-related differences in disease trajectory. As immune responses are in part regulated by metabolites, we examined whether the serum metabolome has sex-specificity for immune responses in COVID-19. In males with COVID-19, kynurenic acid (KA) and a high KA to kynurenine (K) ratio was positively correlated with age, inflammatory cytokines, and chemokines and was negatively correlated with T cell responses, revealing that KA production is linked to immune responses in males. Males that clinically deteriorated had a higher KA:K ratio than those that stabilized. In females with COVID-19, this ratio positively correlated with T cell responses and did not correlate with age or clinical severity. KA is known to inhibit glutamate release, and we observed that serum glutamate is lower in patients that deteriorate from COVID-19 compared to those that stabilize, and correlates with immune responses. Analysis of Genotype-Tissue Expression (GTEx) data revealed that expression of kynurenine aminotransferase, which regulates KA production, correlates most strongly with cytokine levels and aryl hydrocarbon receptor activation in older males. This study reveals that KA has a sex-specific link to immune responses and clinical outcomes, in COVID-19 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was in part supported by a gift from the Yale University Rapid Relief Fund, Women Health Research at Yale Pilot Project Program, Fast Grant from Emergent Ventures at the Mercatus Center, Mathers Foundation, the Beatrice Kleinberg Neuwirth Fund, and the Ludwig Family Foundation. IMPACT received support from the Yale COVID-19 Research Resource Fund. A.I. is an Investigator of the Howard Hughes Medical Institute. D.J.K. was a Paul and Daisy Soros Fellow and was supported by a grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) (F30CA236466) and by a MSTP training grant from the NIH (T32GM007205, T32GM136651). S.A.K was supported by CTSA Grant Number UL1TR001863 from the National Center for Advancing Translational Science (NCATS), components of the NIH, and NIH roadmap for Medical Research, and the Lampman Research Fund in Yale Surgical Oncology. Supported was also provided by the Beatrice Kleinberg Neuwirth Fund, Yale Schools of Public Health and Medicine, and NIH U19 AI08992 awarded to A.I.K.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by Yale Human Research Protection Program Institutional Review Boards (FWA00002571, Protocol ID. 2000027690). Informed consent was obtained from all enrolled patients and healthcare workersAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUntargeted metabolomics data, metabolomics protocols, and code is available on the MetaboLights data repository accession number MTBLS1987 (https://www.ebi.ac.uk/metabolights/). Clinical and immunological data is available from previous publication2. https://www.ebi.ac.uk/metabolights/